Verona Pharma Share Discussion Threads

[tradertrev] 21/11/2023 12:22

Haven't been monitoring this but the short interest in VRNA is currently 9.6% which seems pretty huge. Hard to believe this position stays there as the PDUFA date approaches.

[tradertrev] 12/10/2023 14:59

So the ADRs just traded at $13.70 which is equal to the highest trade on 19 December 2022 - the day before the excellent phase 3 trial results were published.
Gap filled! Really didn't expect that!!!

[tradertrev] 22/5/2023 14:45

Looks like the seller has finished

[tradertrev] 09/5/2023 10:44

Cash and equivalents have risen from the $285m (pro-forma that included ATM issuance up to 3rd March 2023) at 31st December 2022, to $291m as at 31st March 2023. This suggests that further ATM issuance of $6m above Q2 cash costs (i.e. a total of $20m, or roughly 1m ADRs) were issued under the ATM facility between 3rd and 31st March 2023.
This could explain some relative sluggishness in the share price over that period.
There is no mention of ATM issuance in today's statement in relation to both the total cash and equivalents and the liquidity available to last until at least the end of 2025. This suggests to me that they may have stopped issuing further shares under the ATM facility, at least for the time being.
This could help the shares move on a bit.

[timbo003] 18/4/2023 20:52

See today's announcement from GSK regarding their acquisition of Bellus Health and commentary from Fierce Biotech






Bellus appear to be a one trick pony developing camlipixant, a "highly selective P2X3 antagonist and potential best-in-class treatment for refractory chronic cough (RCC)" which is currently undergoing (two) Phase III clinical trials (due to report in H2 2024 and 2025)

GSK are paying $2Bn (about twice the preannouncement market cap) for Bellus,

Estimates for the prevalence of chronic cough are not dissimilar to estimates for COPD, so the addressable market is probably similar for both indications.

Based on the Phase II data Camlipixant could become best in class amongst P2X3 antagonists, but until they receive the Phase III results they will not know either way. Compare and contrast with Verona's Ensifentrine which is first in class (i.e. unique) and has demonstrated an exceptional reduction (circa 40%) for exacerbations in COPD patients in two pivotal Phase III clinical trials.

So if Bellus is worth £2Bn, what should Veronaa Pharma be worth?

The current Market cap for Verona is just $1.7Bn, which seems way too low if you use Bellus as a yardstick.

[timbo003] 18/4/2023 20:51

edit : repeat post

[tradertrev] 13/4/2023 12:14

Oh, have I offended someone? Didn't think that would generate a thumbs down!

[tradertrev] 13/4/2023 10:43

Trust everyone has seen that our China partner has dosed its first patient in the Phase 3 trial over there. This is running concurrently with the Phase 1 (toxicity) trial. Got to love the way the Chinese do things!! (Although tbf there is a huge body of data showing no toxicity issues in Europe and US.)

[haff1] 10/3/2023 10:18

Not looking good.....

[haff1] 09/2/2023 09:54

been here for more than 10 years so have seen the comings and goings long enough to be cautious...

[tradertrev] 07/2/2023 07:04

The graph shows that the price has fallen back after a barnstormingly good year. Yesterday's rise is very close to breaking the short term downtrend.
Don't understand your unchanged expectations Haff. Maybe holding the chart the right way up would help?

[haff1] 06/2/2023 09:58

Not good from a TA perspective: lowering highs and lowering lows....the graph is indicating a fall!! So no change in VRP expectaions....

[joeblogg2] 22/12/2022 14:39

thanks tim , will keep an eye on it again

[timbo003] 22/12/2022 14:31

>>>joeblog, I don't really know the answer to that one.

I am at last up on this one, albeit not by much, my average buy price was around 2.2p/share (pre-consolidation) most of which were acquired in the 2014 open offer. I'm a bit annoyed with myself for not topping after the first phase III results (ENHANCE2) as those results were truely exceptional, I suspect the shares have further to run, especially in the lead up to news regarding FDA and EMA approval (with a truely differentiated label) - which now seems rather likely, but I think I will just stick with what I have got for now (having missed the obvious time to top up after ENHANCE2)

[haroldthegreat] 22/12/2022 11:38

Thanks Tim .So have a long way to go till one profits if one purchased at peak . The million $ question now is how high will they go before falling back .

[timbo003] 22/12/2022 11:21

Your recollection is spot on Tradertrev

Here is the historical chart up to the delisting on Aim and a table to show the price equivalents of the old pre-consolidation shares, the post-consolidation shares and the ADRs

[tradertrev] 22/12/2022 08:53

Harold - not hard facts, but I seem to recall that if you went back far enough on old UK charts you would see the equivalent of at least £20 per UK share. This was diluted many times by share issuance at ever decreasing prices. £20 per UK share would be the equivalent now of $133 per ADR (8 shares per ADR), although at more normal exchange rates back then (say $1.50) it would be more like $107.
I suspect this is all rather academic however.

[haroldthegreat] 21/12/2022 22:26

secretsqu1 Sep '09 - 17:20 - 4 of 30
0 0 0
Bought in here at 4.75p and top sliced it at 11p last week. Letting the free shares run theie course and hoping for 20p.


found above on an old board

if you look at chart of uk prices they quote £9.20 so there must have been massive consolidations over the years .
. what consolidations or rights issues were there ?

all tooooooooooooooooooo much for my little brain ! Tim where are you ????????????????????

[haroldthegreat] 21/12/2022 21:15

Tim you are the expert . What is the highest price these achieved before they listed in the States ?

[mo78000] 21/12/2022 12:58

I can vaguely remember going into the 20s

[boystown] 21/12/2022 08:06

I sold at $18.20 yesterday at a profit after about 8 years iirc and recycled the money into IPO. I know I'll probably live to regret this.

[haroldthegreat] 20/12/2022 23:59

what was the highest price achieved per share in uk prior to us listing ?

[mo78000] 20/12/2022 12:43

I have been following the chat across the pond...some of the figures been quoted are bit insane. https://stocktwits.com/symbol/VRNA